Aeterna Zentaris (AEZS) Stock Price, News & Analysis

Company Overview

Aeterna Zentaris Inc. is a specialty biopharmaceutical company headquartered in Laval, Quebec, with a strategic focus on developing treatments in the fields of oncology and endocrinology. The company advances both proprietary and partnered programs, leveraging peptide- and small-molecule–based technologies to address unmet medical needs. Through its targeted approach, Aeterna Zentaris aims to bring novel diagnostics and therapies to market, often in collaboration with global pharmaceutical partners.

The company’s lead commercial product is macimorelin, an orally administered diagnostic agent for adult growth hormone deficiency. Marketed under the brand name Macrilen in the United States through a licensing agreement with Ipsen, macimorelin offers a non-invasive alternative to traditional growth hormone stimulation tests. Beyond its marketed product, Aeterna Zentaris maintains a pipeline of oncology candidates, including targeted cytotoxic conjugates designed to deliver anti-cancer agents directly to tumor cells expressing luteinizing hormone-releasing hormone (LHRH) receptors. These pipeline assets are undergoing various stages of preclinical and clinical development aimed at prostate, endometrial and other receptor-positive malignancies.

In addition to its proprietary research, Aeterna Zentaris has forged partnerships to expand the commercial reach of its assets and to co-develop new candidates. The company conducts its research and early-stage development in Canada while engaging clinical trial sites across North America and Europe. This geographic footprint enables Aeterna Zentaris to access diverse patient populations and to optimize regulatory strategies in multiple jurisdictions.

Aeterna Zentaris is led by an executive team with extensive experience in biopharmaceutical R&D, regulatory affairs and commercial operations. Supported by a board of directors featuring industry veterans, the company pursues a disciplined development strategy, balancing near-term commercial opportunities with longer-term innovation. By combining diagnostic platforms with targeted therapeutics, Aeterna Zentaris seeks to carve out a niche in specialty care areas where precision and patient convenience are paramount.

Key Stats

• Today's Range: $2.97 to $3.16
• 50-Day Range: $2.63 to $3.91
• 52-Week Range: $3.96 to $12.00
• Volume: 3,223 shs
• Average Volume: 7,305 shs
• Market Capitalization: $5.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 11/04/2021
• Today: 5/25/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AEZS
• CIK: 1113423
• Web: www.zentaris.com
• Phone: (418) 652-8525
• Fax: 418-948-9191
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($14.86)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$16.55 million
• Net Margins: -760.32%
• Pretax Margin: -760.28%
• Return on Equity: -83.45%
• Return on Assets: -45.76%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.94
• Quick Ratio: 5.93

Sales & Book Value

• Annual Sales: $2.37 million
• Price / Sales: 2.33
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $14.99 per share
• Price / Book: 0.21

Miscellaneous

• Outstanding Shares: 1,793,000
• Free Float: 1,791,000
• Market Cap: $5.52 million
• Optionable: No Data
• Beta: 1.55